© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Serum High-Density Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk
Affiliations of authors: Section of Epidemiology and Medical Statistics, Institute of Community Medicine, Faculty of Medicine, University of Tromsø, Tromsø, Norway (ASF, TW, IT); Section of Medical Statistics, University of Oslo, Oslo, Norway (BV); Keck School of Medicine, University of Southern California, Los Angeles (LB); Ullevål University Hospital, Oslo (IT)
Correspondence to: Anne-Sofie Furberg, MD, PhD, Institute of Community Medicine, Faculty of Medicine, University of Tromsø, N-9037 Tromsø, Norway (e-mail: anne-sofie.furberg{at}ism.uit.no)
Background: The prevalence of metabolic syndrome (obesity, glucose intolerance, low serum high-density lipoprotein cholesterol [HDL-C], high serum triglycerides, hypertension) is high and increasing in parallel with an increasing breast cancer incidence worldwide. HDL-C represents an important aspect of the syndrome, yet its role in breast cancer is still undefined. Methods: In two population-based screening surveys during 1977–1983 and 1985–1987, serum HDL-C was assayed enzymatically among 38 823 Norwegian women aged 17–54 years at entry. Height, weight, blood pressure, serum lipids, fat and energy intake, physical activity, parity, oral contraceptive use, hormone therapy use, alcohol intake, and tobacco use were also assessed. We used Cox proportional hazards modeling to estimate the relative risk (RR) of breast cancer associated with serum HDL-C levels and to adjust for potential confounding variables. We performed stratified analyses to evaluate effect modification by body mass index (BMI) and menopausal status. All statistical tests were two-sided. Results: During a median follow-up of 17.2 years, we identified 708 cases of invasive breast cancer. In multivariable analysis, the risk of postmenopausal breast cancer was inversely related to quartile of HDL-C (Ptrend = .02). Among women with HDL-C above 1.64 mmol/L (highest quartile) versus below 1.20 mmol/L (lowest quartile), the relative risk was 0.75 (95% confidence interval [CI] = 0.58 to 0.97). The HDL-C association was confined to women in the heavier subgroup (BMI 
25 kg/m2), for whom the relative risk of postmenopausal breast cancer in those with HDL-C above 1.64 mmol/L versus below 1.20 mmol/L was 0.43 (95% CI = 0.28 to 0.67; Ptrend<.001; Pinteraction = .001). Conclusion: Low HDL-C, as part of the metabolic syndrome, is associated with increased postmenopausal breast cancer risk.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. E. Finstad, A. Emaus, S. Tretli, G. Jasienska, P. T. Ellison, A.-S. Furberg, E. A. Wist, and I. Thune Adult Height, Insulin, and 17{beta}-Estradiol in Young Women Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1477 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kim, S. K. Park, W. Han, D.-H. Kim, Y.-C. Hong, E. H. Ha, S.-H. Ahn, D.-Y. Noh, D. Kang, and K.-Y. Yoo Serum High-Density Lipoprotein Cholesterol and Breast Cancer Risk by Menopausal Status, Body Mass Index, and Hormonal Receptor in Korea Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 508 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, W.-Y. So, R. C W Ma, G. T C Ko, A. P S Kong, Q. Wang, C. S Cockram, C.-C. Chow, J. C N Chan, and P. C Y Tong Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes Endocr. Relat. Cancer, June 1, 2008; 15(2): 597 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Emaus, S. Espetvedt, M.B. Veierod, R. Ballard-Barbash, A.-S. Furberg, P.T. Ellison, G. Jasienska, A. Hjartaker, and I. Thune 17-{beta}-Estradiol in relation to age at menarche and adult obesity in premenopausal women Hum. Reprod., April 1, 2008; 23(4): 919 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. DuSell, M. Umetani, P. W. Shaul, D. J. Mangelsdorf, and D. P. McDonnell 27-Hydroxycholesterol Is an Endogenous Selective Estrogen Receptor Modulator Mol. Endocrinol., January 1, 2008; 22(1): 65 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Rose, S. M. Haffner, and J. Baillargeon Adiposity, the Metabolic Syndrome, and Breast Cancer in African-American and White American Women Endocr. Rev., December 1, 2007; 28(7): 763 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Xue and K. B Michels Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 823S - 835S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Lim, T. Gayles, H. A. Katki, R. Stolzenberg-Solomon, S. J. Weinstein, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma Cancer Res., June 1, 2007; 67(11): 5569 - 5574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cowey and R. W. Hardy The Metabolic Syndrome: A High-Risk State for Cancer? Am. J. Pathol., November 1, 2006; 169(5): 1505 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lund Haheim, T. F. Wisloff, I. Holme, and P. Nafstad Metabolic Syndrome Predicts Prostate Cancer in a Cohort of Middle-aged Norwegian Men Followed for 27 Years Am. J. Epidemiol., October 15, 2006; 164(8): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Eliassen, G. A. Colditz, B. Rosner, W. C. Willett, and S. E. Hankinson Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer Arch Intern Med, October 24, 2005; 165(19): 2264 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
A.-S. Furberg, G. Jasienska, N. Bjurstam, P. A. Torjesen, A. Emaus, S. F. Lipson, P. T. Ellison, and I. Thune Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. The Norwegian EBBA Study Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, M. Pettinger, M. L. Stefanick, B. V. Howard, Y. Mossavar-Rahmani, and A. McTiernan Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications J. Clin. Oncol., November 15, 2004; 22(22): 4507 - 4513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Wilkin and L. D Voss Metabolic syndrome: maladaptation to a modern world J R Soc Med, November 1, 2004; 97(11): 511 - 520. [Full Text] [PDF]
|
|